Trends in Postoperative Opioid Use in Norway 2011–2018: A Nationwide Registry‐Based Study
Basic & Clinical Pharmacology & Toxicology · 2025-06 · 136 (6)
DOI: 10.1111/bcpt.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 27.04.2025. Verfasst von Per-Jostein Samuelsen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regional Medicines Information and Pharmacovigilance Centre (RELIS), University Hospital of North Norway, Tromsø, Norway. Hauptthemen laut MEDLINE: Analgesics, Opioid, Postoperative Pain, Practice Patterns, Physicians'. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Northern Norway Regional Health Authority, Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Research Council of Norway.
Abstract (Originalsprache)
Little is known about the overall trends in postoperative opioid use in a Nordic setting. We investigated the trends in Norway between 2011 and 2018. We linked the Norwegian Prescription Database, the Norwegian Patient Registry, the Cancer Registry of Norway and the Cause of Death Registry. Postoperative opioid use was defined as the first opioid dispensing per year within 14 days of a NOMESCO Classification of Surgical Procedure code. We excluded patients with cancer or opioid maintenance therapy. We calculated period prevalence (Norwegian population ≥ 15 years as the denominator), substance distribution, initial amount and proportion of long‐acting formulations. Among 746 435 postoperative opioid users ≥ 15 years, the period prevalence increased from 27.0/1000 in 2011 to 30.0/1000 in 2018 (long‐term use: 2.0 to 3.3/1000). Codeine was most frequent (67%) in 2011, while codeine and tramadol were equally dispensed (41% and 43%) in 2018; oxycodone increased from 3% to 12%. The initial amount increased for opioids as a group but declined for oxycodone (1236 morphine milligram equivalents [MME]/patient to 914 MME/patient) and tramadol (233 MME/patient to 219 MME/patient). Long‐acting depot formulations increased from 5% to 12%. Over time, postoperative opioid use increased, with a shift toward more tramadol and oxycodone in lower initial amounts, and increased use of long‐acting formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regional Medicines Information and Pharmacovigilance Centre (RELIS), University Hospital of North Norway, Tromsø, Norway.
- Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Pain Management and Research, Oslo University Hospital, Oslo, Norway.
- Department of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Per-Jostein Samuelsen
Förderung
- Northern Norway Regional Health Authority
- Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital
- Research Council of Norway
- Helse Nord RHF
- Norges Forskningsråd
Zitieren
APA
Samuelsen, P. J., Hjellvik, V., Odsbu, I., Stubhaug, A., Skurtveit, S., & Vambheim, S. M. (2025). Trends in Postoperative Opioid Use in Norway 2011–2018: A Nationwide Registry‐Based Study. Basic & Clinical Pharmacology & Toxicology, 136(6). https://doi.org/10.1111/bcpt.70040
Vancouver
Samuelsen PJ, Hjellvik V, Odsbu I, Stubhaug A, Skurtveit S, Vambheim SM. Trends in Postoperative Opioid Use in Norway 2011–2018: A Nationwide Registry‐Based Study. Basic & Clinical Pharmacology & Toxicology. 2025;136(6). doi:10.1111/bcpt.70040
BibTeX
@article{Samuelsen2025,
author = {Samuelsen, Per-Jostein and Hjellvik, Vidar and Odsbu, Ingvild and Stubhaug, Audun and Skurtveit, Svetlana and Vambheim, Sara Magelssen},
title = {Trends in Postoperative Opioid Use in Norway 2011–2018: A Nationwide Registry‐Based Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
volume = {136},
number = {6},
doi = {10.1111/bcpt.70040}
}
EUVIMED